Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.
This trial is active, not recruiting.
|Start date||September 2005|
|End date||June 2016|
|Trial size||50 participants|
|Trial identifier||NCT00227461, AMBarrett1, none applicable|
The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.
|Endpoint classification||safety/efficacy study|
|Intervention model||crossover assignment|
Speech and language assessment
time frame: 6 months - 1year
time frame: 6 months to 1 year
Male or female participants at least 18 years old.
- Can give consent
- Renal failure
- Other neurological condition
|Official title||Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.|
|Principal investigator||A.M. Barrett, MD|
|Description||In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.|
Call for more information